vTv Therapeutics Cash Position Increases to $88.9M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy VTVT?
The company's cash position as of December 31, 2025, was $88.9M compared to $36.7M as of December 31, 2024. "In 2025, vTv delivered meaningful clinical and corporate progress that positions us for a highly productive 2026," said Paul Sekhri, chairman, president and CEO of vTv Therapeutics. "During the course of the year, we initiated patient dosing in the Phase 3 CATT1 trial evaluating cadisegliatin as an adjunct to insulin for the treatment of type 1 diabetes, strengthened our balance sheet with an $80.0 million financing with leading healthcare investors, and continued to expand our intellectual property estate supporting cadisegliatin. In early 2026, we secured an additional $20.0 million in non-dilutive funding."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTVT
Wall Street analysts forecast VTVT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.100
Low
40.00
Averages
51.33
High
67.00
Current: 35.100
Low
40.00
Averages
51.33
High
67.00
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
vTv Therapeutics Reports 2025 Financials and Pipeline Progress
- Financial Performance: vTv Therapeutics reported a net loss of $7.1 million in Q4 2025, translating to a basic loss of $0.58 per share, which is an increase from the $3.6 million loss in the same quarter of 2024, highlighting the pressure from rising R&D expenditures.
- R&D Progress: The company initiated the Phase 3 CATT1 trial for Cadisegliatin in 2025, and despite initial slow patient recruitment, the acceleration in enrollment momentum was achieved by increasing participating sites and enhancing patient engagement, with completion expected by Q3 2026.
- Financial Position: vTv ended 2025 with $88.9 million in cash and cash equivalents, bolstered by an $80 million private placement completed in September 2025, with management indicating that this funding will support operations well past the anticipated topline readout of the Phase 3 trial.
- Strategic Partnership: The company received a $20 million milestone payment from Newsoara Biopharma under an amended licensing agreement, which includes up to $50 million in development milestones and $65 million in sales milestones, indicating potential expansion of Cadisegliatin's reach into type 2 diabetes.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting the latest market views and expectations for these firms.
- Market Dynamics Observation: While specific company names are not disclosed, changes in analyst ratings typically influence investor confidence, thereby directly impacting the market performance of the related stocks.
- Investor Decision Reference: Investors considering buying FPI stock can refer to these analyst rating changes to make more informed investment decisions, although specific recommendations are not provided.
- Transparent Information Source: Benzinga's market news and data aim to provide investors with comprehensive insights into analyst rating changes, helping them better understand market dynamics.
See More
vTv Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: vTv Therapeutics reported a Q4 GAAP EPS of -$0.58, beating expectations by $0.50, indicating improved financial management and increased market confidence in the company's prospects.
- Significant Cash Reserves Growth: As of December 31, 2025, the company's cash position rose to $88.9 million from $36.7 million in 2024, primarily due to proceeds from the private placement financing announced on September 2, 2025, enhancing the company's financial flexibility.
- Far-Reaching Financing Impact: The successful private placement not only improved cash flow but also provided funding for future R&D and market expansion, expected to accelerate the clinical trial process for Cadisegliatin.
- Future Catalysts: With the upcoming readout of Cadisegliatin's Phase 3 CATT1 trial results, vTv Therapeutics is poised for new market catalysts that could further drive stock price appreciation and attract more investor interest.
See More
Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target
- vTv Therapeutics Rating: Roth Capital analyst Adam Walsh initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $58, indicating significant upside potential from its current price of $33.54.
- MasTec Upgrade: Cantor Fitzgerald analyst Manish Somaiya initiated coverage on MasTec Inc (NYSE:MTZ) with an Overweight rating and a price target of $274, suggesting strong market optimism given its current price of $244.57.
- e.l.f. Beauty Analysis: Citigroup analyst Filippo Falorni initiated coverage on e.l.f. Beauty Inc (NYSE:ELF) with a Buy rating and a price target of $110, reflecting confidence in the brand's growth potential from its current price of $95.34.
- Decoy Therapeutics Outlook: Ladenburg Thalmann analyst Kevin DeGeeter initiated coverage on Decoy Therapeutics Inc (NASDAQ:DCOY) with a Buy rating and a price target of $2.5, indicating positive expectations for its market performance from its current price of $0.7505.
See More
vTv Therapeutics Initiated with Buy Rating and $67 Price Target
- Analyst Rating Upgrade: TD Cowen analyst Ritu Baral initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $67, representing significant upside from Friday's close of $39.60, indicating strong market optimism about the company's future growth prospects.
- Positive Market Reaction: Following the analyst rating announcement, vTv Therapeutics' stock is expected to gain traction, with investors showing heightened interest in its potential market performance, which could attract more capital inflow.
- SharpLink Gaming Rating Boost: Cantor Fitzgerald analyst Brett Knoblauch initiated coverage on SharpLink Gaming Inc (NASDAQ:SBET) with an Overweight rating and a price target of $15, indicating a notable increase from Friday's close of $9.69, reflecting recognition of its business growth potential.
- Dual Ratings for Lumexa Imaging: Both Leerink Partners and Jefferies initiated coverage on Lumexa Imaging Holdings Inc (NASDAQ:LMRI) with Outperform ratings and a price target of $23, showcasing a strong consensus in the market regarding the company's promising outlook.
See More
vTv Therapeutics Upgraded to Zacks Rank #2 (Buy) Reflecting Positive Earnings Outlook
- Rating Upgrade: vTv Therapeutics has recently been upgraded to Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates that could positively impact its stock price.
- Earnings Estimate Growth: Over the past three months, the Zacks Consensus Estimate for the company has increased by 9.2%, indicating enhanced analyst confidence in its future profitability.
- Market Performance Potential: The Zacks rating system places vTv Therapeutics in the top 20% of stocks, suggesting its superior earnings estimate revision feature may lead to market-beating returns in the near term.
- Investor Confidence: As earnings estimates rise, institutional investors may increase their stakes in vTv Therapeutics, potentially driving the stock price higher and reflecting improvements in the company's fundamentals.
See More
vTv Therapeutics Reports 2025 Financials and Pipeline Progress
- Financial Performance: vTv Therapeutics reported a net loss of $7.1 million in Q4 2025, translating to a basic loss of $0.58 per share, which is an increase from the $3.6 million loss in the same quarter of 2024, highlighting the pressure from rising R&D expenditures.
- R&D Progress: The company initiated the Phase 3 CATT1 trial for Cadisegliatin in 2025, and despite initial slow patient recruitment, the acceleration in enrollment momentum was achieved by increasing participating sites and enhancing patient engagement, with completion expected by Q3 2026.
- Financial Position: vTv ended 2025 with $88.9 million in cash and cash equivalents, bolstered by an $80 million private placement completed in September 2025, with management indicating that this funding will support operations well past the anticipated topline readout of the Phase 3 trial.
- Strategic Partnership: The company received a $20 million milestone payment from Newsoara Biopharma under an amended licensing agreement, which includes up to $50 million in development milestones and $65 million in sales milestones, indicating potential expansion of Cadisegliatin's reach into type 2 diabetes.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting the latest market views and expectations for these firms.
- Market Dynamics Observation: While specific company names are not disclosed, changes in analyst ratings typically influence investor confidence, thereby directly impacting the market performance of the related stocks.
- Investor Decision Reference: Investors considering buying FPI stock can refer to these analyst rating changes to make more informed investment decisions, although specific recommendations are not provided.
- Transparent Information Source: Benzinga's market news and data aim to provide investors with comprehensive insights into analyst rating changes, helping them better understand market dynamics.
See More
vTv Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: vTv Therapeutics reported a Q4 GAAP EPS of -$0.58, beating expectations by $0.50, indicating improved financial management and increased market confidence in the company's prospects.
- Significant Cash Reserves Growth: As of December 31, 2025, the company's cash position rose to $88.9 million from $36.7 million in 2024, primarily due to proceeds from the private placement financing announced on September 2, 2025, enhancing the company's financial flexibility.
- Far-Reaching Financing Impact: The successful private placement not only improved cash flow but also provided funding for future R&D and market expansion, expected to accelerate the clinical trial process for Cadisegliatin.
- Future Catalysts: With the upcoming readout of Cadisegliatin's Phase 3 CATT1 trial results, vTv Therapeutics is poised for new market catalysts that could further drive stock price appreciation and attract more investor interest.
See More
Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target
- vTv Therapeutics Rating: Roth Capital analyst Adam Walsh initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $58, indicating significant upside potential from its current price of $33.54.
- MasTec Upgrade: Cantor Fitzgerald analyst Manish Somaiya initiated coverage on MasTec Inc (NYSE:MTZ) with an Overweight rating and a price target of $274, suggesting strong market optimism given its current price of $244.57.
- e.l.f. Beauty Analysis: Citigroup analyst Filippo Falorni initiated coverage on e.l.f. Beauty Inc (NYSE:ELF) with a Buy rating and a price target of $110, reflecting confidence in the brand's growth potential from its current price of $95.34.
- Decoy Therapeutics Outlook: Ladenburg Thalmann analyst Kevin DeGeeter initiated coverage on Decoy Therapeutics Inc (NASDAQ:DCOY) with a Buy rating and a price target of $2.5, indicating positive expectations for its market performance from its current price of $0.7505.
See More
vTv Therapeutics Initiated with Buy Rating and $67 Price Target
- Analyst Rating Upgrade: TD Cowen analyst Ritu Baral initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $67, representing significant upside from Friday's close of $39.60, indicating strong market optimism about the company's future growth prospects.
- Positive Market Reaction: Following the analyst rating announcement, vTv Therapeutics' stock is expected to gain traction, with investors showing heightened interest in its potential market performance, which could attract more capital inflow.
- SharpLink Gaming Rating Boost: Cantor Fitzgerald analyst Brett Knoblauch initiated coverage on SharpLink Gaming Inc (NASDAQ:SBET) with an Overweight rating and a price target of $15, indicating a notable increase from Friday's close of $9.69, reflecting recognition of its business growth potential.
- Dual Ratings for Lumexa Imaging: Both Leerink Partners and Jefferies initiated coverage on Lumexa Imaging Holdings Inc (NASDAQ:LMRI) with Outperform ratings and a price target of $23, showcasing a strong consensus in the market regarding the company's promising outlook.
See More
vTv Therapeutics Upgraded to Zacks Rank #2 (Buy) Reflecting Positive Earnings Outlook
- Rating Upgrade: vTv Therapeutics has recently been upgraded to Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates that could positively impact its stock price.
- Earnings Estimate Growth: Over the past three months, the Zacks Consensus Estimate for the company has increased by 9.2%, indicating enhanced analyst confidence in its future profitability.
- Market Performance Potential: The Zacks rating system places vTv Therapeutics in the top 20% of stocks, suggesting its superior earnings estimate revision feature may lead to market-beating returns in the near term.
- Investor Confidence: As earnings estimates rise, institutional investors may increase their stakes in vTv Therapeutics, potentially driving the stock price higher and reflecting improvements in the company's fundamentals.
See More
